Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015 : a systematic review and modelling study

Tools
- Tools
+ Tools

Shi, Ting, McAllister, David A., O'Brien, Katherine L., Simoes, Eric A. F., Madhi, Shabir A., Gessner, Bradford D., Polack, Fernando P., Balsells, Evelyn, Acacio, Sozinho, Aguayo, Claudia et al.
(2017) Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015 : a systematic review and modelling study. The Lancet, 390 (10098). pp. 946-958. doi:10.1016/S0140-6736(17)30938-8 ISSN 0140-6736.

[img]
Preview
PDF
WRAP-global-regional-national-disease-burden-estimates-Nokes-2017.pdf - Accepted Version - Requires a PDF viewer.
Available under License Creative Commons Attribution 4.0.

Download (2289Kb) | Preview
Official URL: http://dx.doi.org/10.1016/S0140-6736(17)30938-8

Request Changes to record.

Abstract

Background:

We have previously estimated that respiratory syncytial virus (RSV) was associated with 22% of all episodes of (severe) acute lower respiratory infection (ALRI) resulting in 55 000 to 199 000 deaths in children younger than 5 years in 2005. In the past 5 years, major research activity on RSV has yielded substantial new data from developing countries. With a considerably expanded dataset from a large international collaboration, we aimed to estimate the global incidence, hospital admission rate, and mortality from RSV-ALRI episodes in young children in 2015.

Methods:

We estimated the incidence and hospital admission rate of RSV-associated ALRI (RSV-ALRI) in children younger than 5 years stratified by age and World Bank income regions from a systematic review of studies published between Jan 1, 1995, and Dec 31, 2016, and unpublished data from 76 high quality population-based studies. We estimated the RSV-ALRI incidence for 132 developing countries using a risk factor-based model and 2015 population estimates. We estimated the in-hospital RSV-ALRI mortality by combining in-hospital case fatality ratios with hospital admission estimates from hospital-based (published and unpublished) studies. We also estimated overall RSV-ALRI mortality by identifying studies reporting monthly data for ALRI mortality in the community and RSV activity.

Findings:

We estimated that globally in 2015, 33·1 million (uncertainty range [UR] 21·6–50·3) episodes of RSV-ALRI, resulted in about 3·2 million (2·7–3·8) hospital admissions, and 59 600 (48 000–74 500) in-hospital deaths in children younger than 5 years. In children younger than 6 months, 1·4 million (UR 1·2–1·7) hospital admissions, and 27 300 (UR 20 700–36 200) in-hospital deaths were due to RSV-ALRI. We also estimated that the overall RSV-ALRI mortality could be as high as 118 200 (UR 94 600–149 400). Incidence and mortality varied substantially from year to year in any given population.

Interpretation:

Globally, RSV is a common cause of childhood ALRI and a major cause of hospital admissions in young children, resulting in a substantial burden on health-care services. About 45% of hospital admissions and in-hospital deaths due to RSV-ALRI occur in children younger than 6 months. An effective maternal RSV vaccine or monoclonal antibody could have a substantial effect on disease burden in this age group.

Funding:

The Bill & Melinda Gates Foundation.

Item Type: Journal Article
Subjects: R Medicine > RJ Pediatrics > RJ101 Child Health. Child health services
Divisions: Faculty of Science, Engineering and Medicine > Science > Life Sciences (2010- )
Library of Congress Subject Headings (LCSH): Children -- Diseases, Respiratory syncytial virus -- Mortality -- Statistics
Journal or Publication Title: The Lancet
Publisher: Lancet Publishing Group
ISSN: 0140-6736
Official Date: 2 September 2017
Dates:
DateEvent
2 September 2017Published
6 July 2017Available
Volume: 390
Number: 10098
Page Range: pp. 946-958
DOI: 10.1016/S0140-6736(17)30938-8
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Open Access (Creative Commons)
Date of first compliant deposit: 1 August 2017
Date of first compliant Open Access: 1 August 2017
Funder: Bill & Melinda Gates Foundation, China Scholarship Council (CSC), Wellcome Trust (London, England), Innovative Medicines Initiative (IMI) , Horizon 2020 (European Commission) (H2020), Japan. Monbu Kagakushō [Japan. Ministry of Education, Culture, Sports, Science and Technology] (MEXT), Japan. Iryō kenkyū kaihatsu kikō [Japan Agency for Medical Research and Development] (AMED)
Grant number: OPP1088499, OPP1017641 (Bill & Melinda Gates Foundation), 201492/Z/16/Z, OXF-COR03, 02975, 098532 (Wellcome Trust (London, England)), 116019 (IMI)
RIOXX Funder/Project Grant:
Project/Grant IDRIOXX Funder NameFunder ID
OPP1088499Bill and Melinda Gates Foundationhttp://dx.doi.org/10.13039/100000865
OPP1017641Bill and Melinda Gates Foundationhttp://dx.doi.org/10.13039/100000865
UNSPECIFIEDChina Scholarship Councilhttp://dx.doi.org/10.13039/501100004543
201492/Z/16/ZWellcome Trusthttp://dx.doi.org/10.13039/100010269
OXF-COR03Wellcome Trusthttp://dx.doi.org/10.13039/100010269
02975Wellcome Trusthttp://dx.doi.org/10.13039/100010269
098532Wellcome Trusthttp://dx.doi.org/10.13039/100010269
116019Innovative Medicines Initiative (IMI)UNSPECIFIED
UNSPECIFIEDH2020 European Research Councilhttp://dx.doi.org/10.13039/100010663
UNSPECIFIEDJapan. Monbu Kagakushō. [MEXT] Ministry of Education, Culture, Sports, Science and Technologyhttp://dx.doi.org/10.13039/501100001700
UNSPECIFIEDJapan. Iryō kenkyū kaihatsu kikō. Japan Agency for Medical Research and Developmenthttp://dx.doi.org/10.13039/100009619

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics

twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us